Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients

MeSH terms

• Aged
• Antibodies, Monoclonal / administration & dosage
• Antibodies, Monoclonal, Humanized
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Bevacizumab
• Biomarkers*
• Combined Modality Therapy
• Dose-Response Relationship, Drug
• Female
• Fluorouracil / administration & dosage
• Humans
• Male
• Maximum Tolerated Dose
• Middle Aged
• Neovascularization, Pathologic / prevention & control*
• Prognosis
• Radiotherapy Dosage
• Rectal Neoplasms / blood supply
• Rectal Neoplasms / drug therapy*
• Rectal Neoplasms / radiotherapy*
• Survival Rate